Biote Corp. reported its first quarter 2025 financial results on May 7, 2025, with total revenue increasing 4.7% year-over-year to $49.0 million. This growth was primarily driven by a 25.5% increase in dietary supplement revenue to $9.3 million and a 156% increase in service revenue to $2.0 million.
Despite overall revenue growth, core pellet procedure revenue experienced a 3.6% decline to $36.0 million, impacted by reduced commercial effectiveness and a slowdown in new clinic additions following the rollout of the enhanced Clinical Decision Support Software (CDSS). The company achieved a gross profit margin of 74.3%, a 300 basis point improvement, attributed to cost savings from the vertical integration of its 503B manufacturing facility.
Net income for the quarter was $15.8 million, including a $10.7 million gain from the change in fair value of earnout liabilities, resulting in diluted earnings per share of $0.37. Adjusted EBITDA decreased 3.4% to $13.8 million, with an Adjusted EBITDA margin of 28.1%.
Alongside the earnings report, Biote announced a strategic organizational restructuring designed to drive sustainable, profitable growth. This plan includes realigning the commercial team, transitioning support functions to field sales roles to increase the sales force by approximately 25%, streamlining sales leadership, and updating compensation structures.
The restructuring aims to accelerate new provider wins, strengthen relationships with existing top-tier clinics, and improve commercial accountability and discipline. Management maintained its full-year 2025 guidance, projecting revenue between $202 million and $208 million and Adjusted EBITDA between $59 million and $64 million, anticipating a reacceleration of procedure revenue growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.